12 Hot Stocks to Buy According to Analysts

4. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Average Upside Potential: 63.95%

Gain Over Past 6 Months: 39.04%

Corcept Therapeutics Incorporated (NASDAQ:CORT) serves as a commercial-stage company involved in the discovery and development of medications to treat severe oncologic, endocrinologic, neurologic, and metabolic disorders by modulating the effects of the hormone cortisol. The firm follows a mission to unlock the potential of cortisol modulation and revolutionize serious disease treatment.

The firm leads the way in the research and development of the molecules that regulate cortisol activity at the glucocorticoid receptor, cortisol modulators, having discovered over 1,000 selective proprietary cortisol modulators to date. Corcept is making strides in healthcare with things like its drug, Korlym, the first medication approved by the FDA to serve patients with endogenous hypercortisolism. While the firm logged a 48% revenue increase in the recent quarter, it increased Korlym prescribers and more patients received Korlym treatment than ever before.

Corcept Therapeutics Incorporated (NASDAQ:CORT) claimed to have set itself for a transformative last quarter of 2024, being all set to submit its NDA (new drug application) for relacorilant as a treatment for patients with hypercortisolism by the end of the year. CORT also expects to release data from its pivotal study in women with platinum-resistant ovarian cancer, its study in patients with amyotrophic lateral sclerosis, and the treatment phase of its CATALYST study in patients with Cushing’s syndrome. CATALYST is the largest study ever done of hypercortisolism in patients with difficult-to-control diabetes.